CLONMEL, Ireland – Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, has announced today that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia. SH-111 is a lifesaving treatment that is often in shortage and the...
Latest News
CLONMEL, Ireland – Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, announces the appointment of Chief Commercial Officer Nicholas Holsman, a highly experienced U.S. industry executive with in-depth experience in scaling oncology & specialty pharma enterprises. Shorla specializes in developing innovative oncology drugs, with a focus on orphan and pediatric cancers....
– Favorable reimbursement policies across many countries are estimated to drive the short bowel syndrome market during the forecast period – High cost of parenteral nutrition will boost the demand for SBS drugs extensively, eventually increasing the growth rate of the global market ALBANY – Transparency Market Research, New York: The growing prevalence...
Compared with standard whole-body magnetic resonance imaging (WBMRI), a short WBMRI protocol may reduce the length of MRI tests, while maintaining high sensitivity and specificity, among patients with multiple myeloma (MM) undergoing diagnostic testing, according to research published in Diagnostics. MM is the second-most common hematologic cancer, following non-Hodgkin lymphomas, and...
PRINCETON, N.J. & TOKYO & WALTHAM, Mass. — Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC); Otsuka Pharmaceutical, Co. Ltd. (Otsuka); and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of...
Chengdu, China – Prof. Changyang Gong’s team (Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) wrote this review, in which Dr. Xianzhou Huang leads most of the research. Rapid growth in nanoparticles as delivery systems holds vast promise to promote therapeutic approaches...
Montreal , Canada – UdeM’s Stéphanie Forté and co-researchers in Canada and Brazil have shown how people with sickle cell disease or sickle cell trait have a higher chance of dying from COVID-19 than the general population. Patients with sickle cell disease and carriers of the sickle cell trait, often...
Imagine glass shards being smashed relentlessly into your bones over and over again. That is what the pain of sickle cell disease feels like, a young girl once told Velvet Brown-Watts, who three years ago started a local support group for sickle cell patients and their families. “I thought that...
SEOUL, South Korea — SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC). The study demonstrated an...
— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, Florida — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine...